People living with HIV to access injectable treatment

PEOPLE living with HIV could soon access injectable treatment which is more convenient and less stigmatising than daily oral pills, scientists at the 9th International Aids Society Conference on HIV Science in Paris, France, have revealed.

Addressing journalists at the conference, researcher Joseph Eron from the University of North Carolina at Chapel Hill, yesterday revealed that results from the 96-week LATTE-2 study found that patients receiving the long-acting injectable tolerated it well and achieved high rates of virologic response.

The four-week dosing schedule is now being evaluated in phase III studies and if approved would improve and encourage adherence rates.

This story is for NewsDay subscribers.